Itepekimab for Sinusitis

Recruiting at 51 trial locations

Overseen By Trial Transparency email recommended (Toll free for US & Canada)

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Sanofi

Must be taking: Mometasone furoate

Must not be taking: Intranasal corticosteroids

Disqualifiers: Nasal tumors, Fungal rhinosinusitis, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 8

Duration: 24 weeks

60 Participants Needed

Trial Summary

What is the purpose of this trial?

ACT18421 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo in male and female participants with chronic rhinosinusitis without nasal polyps (CRSsNP) aged 18 years of age and older. Study details include: * The study duration (4-week screening, 24--week intervention, 20--week safety followup) will be 48 weeks. * The intervention duration will be 24 weeks. * The number of visits will be 7 site visits and 8 phone/remote visits.

Will I have to stop taking my current medications?

The trial requires participants to stop using certain nasal sprays and corticosteroids before and during the study, except for a specific nasal spray provided by the study. If you're on other medications, the protocol doesn't specify, so it's best to discuss with the study team.

What data supports the effectiveness of the drug Itepekimab for sinusitis?

Itepekimab, a drug that targets a protein called interleukin-33, has shown promise in reducing inflammation in asthma patients, which suggests it might help with sinusitis too, as both conditions involve inflammation. However, direct evidence for its effectiveness in sinusitis is not available yet. ^{1 2 3 4 5}

Is itepekimab safe for humans?

Itepekimab has been tested in healthy adults and patients with asthma, and it was well-tolerated with no significant safety concerns reported in these studies. ^{1 3 6 7 8}

How is the drug itepekimab different from other treatments for sinusitis?

Itepekimab is unique because it is a monoclonal antibody that targets interleukin-33, a protein involved in inflammation, which is different from other treatments that often target IgE or other interleukins. This approach may offer a new way to reduce inflammation in sinusitis. ^{1 2 3 5 9}

Research Team

Clinical Sciences & Operations

Principal Investigator

Sanofi

Eligibility Criteria

This trial is for adults with chronic rhinosinusitis without nasal polyps, experiencing symptoms like nasal congestion for at least 12 weeks. They must have had prior sinus surgery, used systemic corticosteroids in the past two years, and show significant sinus inflammation on a CT scan. Women of childbearing potential must agree to effective contraception.

Inclusion Criteria

I've had nasal congestion for at least 12 weeks with a moderate to severe score.

Participants must have at least one of the following features: Prior sinonasal surgery for chronic rhinosinusitis, Treatment with systemic corticosteroid(s) within the prior 2 years before Screening, Worsening symptoms of CRS in the past 2 years which would have required treatment with SCS, Participants must have bilateral inflammation of paranasal sinuses with bilateral ethmoid and maxillary opacification on screening CT scan, Participants must have a Sino-Nasal Outcome Test-22-Items (SNOT-22) score of ≥20 at Visit 1 and Visit 2, Participants who have received a stable dose of mometasone furoate nasal spray (MFNS) for at least 3 weeks before Visit 2, A female participant is eligible to participate if she is not pregnant or breastfeeding and meets contraceptive requirements

Participants must have sinus Total Symptom Score (sTSS) ≥5 at Visit 1 and Visit 2

Exclusion Criteria

I have a tumor in my nasal cavity, it could be cancerous or not.

I do not have any serious health issues that could make this study unsafe for me.

Known allergy to itepekimab or to its excipients

Timeline

Screening

Participants are screened for eligibility to participate in the trial

4 weeks

1 visit (in-person)

Treatment

Participants receive subcutaneous administration of Itepekimab or placebo for 24 weeks

24 weeks

7 site visits, 8 phone/remote visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

20 weeks

Treatment Details

Interventions

• Itepekimab

Trial Overview The study compares two dosing regimens of Itepekimab (an anti-IL-33 antibody) against a placebo over 24 weeks to assess its effectiveness and safety in treating chronic rhinosinusitis without nasal polyps. Participants will also use mometasone furoate nasal spray as part of their treatment.

Participant Groups

Group I: Itepekimab low dose Experimental Treatment 3 Interventions

SC administration of Itepekimab low dose for 24 weeks

Group II: Itepekimab high dose Experimental Treatment 2 Interventions

Subcutaneous (SC) administration of Itepekimab high dose for 24 weeks

Group III: Placebo Placebo Group 2 Interventions

SC administration of matching placebo for 24 weeks

Who Is Running the Clinical Trial?

Sanofi

Lead Sponsor

Trials

2,246

Recruited

4,085,000+

Paul Hudson

Sanofi

Chief Executive Officer since 2019

Degree in Economics from Manchester Metropolitan University

Christopher Corsico

Sanofi

Chief Medical Officer

MD from Cornell University, MPH in Chronic Disease Epidemiology from Yale University

Regeneron Pharmaceuticals

Industry Sponsor

Trials

690

Recruited

948,000+

Founded

1988

Headquarters

Tarrytown, USA

Known For

Precision medicine

Top Products

Dupixent, EYLEA, Libtayo, Praluent

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer since 1988

MD and PhD in Medicine

George Yancopoulos

Regeneron Pharmaceuticals

Chief Medical Officer since 1997

MD from Harvard Medical School

Findings from Research

Itepekimab, a monoclonal antibody targeting interleukin-33, was found to be safe and well-tolerated in two phase I studies involving 63 participants, with no treatment-emergent anti-drug antibody responses detected.

The drug demonstrated effective pharmacokinetics with a long half-life and significant effects on reducing IL-33 levels and blood eosinophils, indicating its potential to reduce airway inflammation in asthma patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Kosloski, MP., Kalliolias, GD., Xu, CR., et al.[2022]

In a phase 2 trial involving 296 adults with moderate-to-severe asthma, itepekimab, a monoclonal antibody targeting interleukin-33, significantly reduced the incidence of asthma control loss compared to placebo, with 22% of patients experiencing loss of control versus 41% in the placebo group.

Itepekimab also improved lung function and quality of life, while showing a similar safety profile to other treatments, indicating its potential as an effective new therapy for asthma management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. Wechsler, ME., Ruddy, MK., Pavord, ID., et al.[2021]

Omalizumab significantly improved various clinical outcomes in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), including reductions in Nasal Polyps Score and Total Nasal Symptom Score, based on a systematic review of four randomized controlled trials involving 303 participants.

The treatment was found to be safe, with no significant difference in the risk of serious adverse events compared to placebo, indicating that omalizumab is well tolerated for managing CRSwNP.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials. Wu, Q., Yuan, L., Qiu, H., et al.[2021]

In a 6-month randomized clinical trial involving subjects with chronic rhinosinusitis (CRS), treatment with the monoclonal antibody omalizumab led to reduced sinus inflammation on imaging, but the difference compared to placebo was not statistically significant.

Omalizumab treatment improved quality of life and symptoms as measured by the Sino-Nasal Outcome Test (SNOT-20) at multiple time points, while the placebo group showed no significant changes, suggesting a potential benefit of omalizumab in CRS management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Pinto, JM., Mehta, N., DiTineo, M., et al.[2022]

Blocking IgE with omalizumab has been shown to provide rapid improvements in clinical symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP), highlighting the importance of IgE-driven inflammatory pathways in this condition.

The review emphasizes the need for further research on diverse patient groups and biomarkers to enhance drug selection and to better understand the mechanisms of omalizumab in treating CRSwNP.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy. Kariyawasam, HH., James, LK.[2021]

In a study of 66 patients with chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab significantly reduced symptoms and nasal polyp scores after 6 and 12 months, indicating its effectiveness as a treatment.

The safety profile of dupilumab was favorable, with only 12.7% of patients experiencing injection site reactions and 11.1% having transient hypereosinophilia, suggesting it is a safe option for managing CRSwNP.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care. Galletti, C., Barbieri, MA., Ciodaro, F., et al.[2023]

Omalizumab is an effective biological drug for treating allergic asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps, showing good efficacy across these conditions.

Despite concerns about a potential increased cancer risk associated with omalizumab, extensive clinical studies and real-world data have consistently demonstrated its safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps. Bagnasco, D., Canevari, RF., Del Giacco, S., et al.[2022]

Omalizumab (Xolair) shows consistent pharmacokinetics and pharmacodynamics in treating chronic rhinosinusitis with nasal polyps (CRSwNP), similar to its effects in allergic asthma, supporting its use in this condition.

In the phase 3 studies, a significant majority of patients (74.2% and 93.0%) achieved target serum free IgE levels after treatment, indicating that the dosing based on body weight and IgE levels is effective for CRSwNP patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps. Zhu, R., Owen, R., Wilkins, J., et al.[2022]

IgE directly promotes eosinophil migration in chronic rhinosinusitis with nasal polyps (CRSwNP) by upregulating the CCR3 receptor, which is not observed in healthy individuals.

Omalizumab treatment effectively reduces eosinophil migration and local IgE levels in patients who respond to the therapy, with baseline local IgE counts being a strong predictor of treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of omalizumab. Yu, J., Yan, B., Shen, S., et al.[2023]

References

1. United States pubmed.ncbi.nlm.nih.gov

Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. [2021]

3. England pubmed.ncbi.nlm.nih.gov

Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials. [2021]

4. Netherlands pubmed.ncbi.nlm.nih.gov

A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. [2022]

5. New Zealand pubmed.ncbi.nlm.nih.gov

Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy. [2021]

6. Switzerland pubmed.ncbi.nlm.nih.gov

Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care. [2023]

7. United States pubmed.ncbi.nlm.nih.gov

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps. [2022]

8. England pubmed.ncbi.nlm.nih.gov

Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of omalizumab. [2023]